← Back to Home

Personalized Cancer Vaccine Succeeds in Phase 3 Trial: Lower Risk of Recurrence After Melanoma Surgery

An mRNA therapy tailored to mutations in each patient’s tumor improved two-year recurrence-free survival when combined with Keytruda. A large trial supports this treatment approach, but whether it extends overall survival requires further follow-up.

By SURL BioNews

Removing a tumor does not necessarily remove the threat of recurrence. For patients with high-risk melanoma, a key goal of treatment after surgery is to prevent the cancer from returning. The personalized cancer vaccine intismeran autogene, jointly developed by Moderna and Merck, has now shown in a phase 3 trial that adding it to existing immunotherapy can help more patients remain alive and free of recurrence.

The study, called INTerpath-001, was first announced to have met its endpoint in August, and the two companies released detailed data in October. After a median follow-up of 24.6 months, the two-year recurrence-free survival rate was 82.2% in the vaccine-plus-Keytruda group, compared with 70.0% in the control group—a difference of 12.2 percentage points. The relative risk of recurrence or death was reduced by 42% over the analysis period; this figure describes the difference in risk between the two groups and cannot be interpreted directly as each patient’s probability of being cured.

The trial enrolled 1,137 patients with stage IIB to IV cutaneous melanoma whose tumors had been completely removed, randomly assigning them in a two-to-one ratio. All participants received Keytruda (pembrolizumab), with either the personalized vaccine or a placebo added. The vaccine was administered every three weeks for up to nine doses. The double-blind study compared how much benefit the vaccine could add to existing postoperative immunotherapy.

This vaccine starts with the patient’s own tumor. Researchers analyze tumor and normal samples to identify mutations specific to the cancer cells, then select “neoantigens” that the immune system may recognize and encode information for up to 34 neoantigens into mRNA. Once inside the body, this information can be used to produce antigens, with the aim of guiding T cells to recognize cancer cells carrying the corresponding markers.

The two therapies therefore have distinct roles: the vaccine seeks to establish an immune response against the tumor, while Keytruda blocks inhibitory PD-1 signaling, reducing the constraints on T cells. This is a treatment strategy designed for patients who already have cancer, rather than a routine vaccine for preventing melanoma in the general population. The current trial results also cannot be applied directly to other cancers.

Beyond efficacy, adding a treatment still comes at a cost. Data released by the companies showed rates of grade 3 to 5 treatment-related adverse events of 14.2% and 13.4% in the two groups, respectively. Common adverse events with the combination included fever, injection-site pain, and fatigue. The study identified no new safety signals, but this does not mean the treatment is without risk.

These results provide stronger clinical support for personalized cancer vaccines, but they cannot yet answer every question. Overall survival data remain immature, and follow-up is continuing. As of the October data release, intismeran remained an investigational therapy, and the two companies were in discussions with regulators. The next questions are whether fewer recurrences will translate into longer lives, and how a manufacturing process tailored to each patient can become part of routine medical care.

References

  1. The Week